Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
JAMA Oncology|May 18, 2023
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialStefania Napolitano, Vincenzo De Falco, Giulia Martini, et al.
ESMO Open|April 3, 2020
Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'Vincenzo De Falco, Luca Poliero, Pietro Paolo Vitello, et al.
International Journal of Molecular Sciences|January 8, 2023
A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with ImmunotherapyElena Élez, Núria Mulet-Margalef, Miriam Sanso, et al.
Molecular Cancer Therapeutics|March 3, 2019
EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal CancerGiulia Martini, Claudia Cardone, Pietro Paolo Vitiello, et al.
Cancers|October 11, 2019
Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution ExperiencePietro Paolo Vitiello, Vincenzo De Falco, Emilio Francesco Giunta, et al.
JAMA Oncology|August 12, 2021
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE TrialErika Martinelli, Giulia Martini, Vincenzo Famiglietti, et al.
Iscience|March 4, 2025
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancerCaterina De Rosa, Floriana Morgillo, Luisa Amato, et al.
Journal of Clinical Medicine|May 14, 2025
Cardio-Oncology Challenges in Elderly PatientsEster Topa, Eliana De Rosa, Alessandra Cuomo, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2020
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancerClaudia Cardone, Bernadette Blauensteiner, Veronica Moreno-Viedma, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2025
Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM studyDavide Ciardiello, Luca Boscolo Bielo, Stefania Napolitano, et al.
Pageof 9